hyderabad
University of Hyderabad’s VeGen Labs secures Rs. 3.7 crore funding to advance cancer drug research
VeGen Labs, an Indian biotech startup, has secured ₹3.765 crores in funding from BIRAC to develop a KRAS inhibitor for lung cancer. This funding will allow the company to complete crucial studies needed for an Investigational New Drug (IND) application, enabling them to start human clinical trials. VeGen Labs is the first Indian company to develop a KRAS inhibitor, marking a significant milestone in the country's cancer research landscape. The funding and VeGen's success highlight India's growing capabilities in drug development and precision medicine, paving the way for future breakthroughs in biotechnology and pharmaceuticals.05:14 PM Mar 03, 2025 IST